Organisation paid for research Program year 2025 Source: CMS Open Payments

Insight Research Institute

Neither a doctor nor a teaching hospital

Research payments

$705,308

43 payments

Through program year 2025, Insight Research Institute is reported as receiving $705,308 in research payments, across 43 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $284,321 15
2024 Research $412,988 27
2022 Research $8,000 1

Breakdown

Who paid Research payments · program years 2022–2025
  1. Nalu Medical, Inc. $230,945 12 payments
  2. Globus Medical, Inc. $133,792 5 payments
  3. Indivior Inc. $131,459 13 payments
  4. Nevro Corp. $90,727 6 payments
  5. Amgen Inc. $36,463 2 payments
  6. Novartis Pharmaceuticals Corporation $33,875 1 payment
  7. AstraZeneca Pharmaceuticals LP $33,698 1 payment
  8. Mitsubishi Tanabe Pharma Development America, Inc. $8,000 1 payment
  9. Solventum Corporation $4,000 1 payment
  10. Mitsubishi Tanabe Pharma America, Inc. $2,350 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2) $230,945 12 payments
  2. A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy $133,792 5 payments
  3. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $131,459 13 payments
  4. PDN-Sensory $90,727 6 payments
  5. Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) $36,463 2 payments
  6. A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $33,875 1 payment
  7. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $33,698 1 payment
  8. A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury $10,350 2 payments
  9. A Prospective, Single-arm, Multi-center, Open Label Trial Evaluating the Continuous Application of Prevena Therapy for up to 14 days $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record